- Kotter I, Vonthein R, Gunaydin I, Muller C, Kanz L, et al. 2003. Behcet’s disease in patients of German and Turkish origin–a comparative study. Adv Exp Med Biol 528:53-8
- Kotter I, Gunaydin I, Stubiger N, Yazici H, Fresko I, et al. 2001. Comparative analysis of the association of HLA-B*51 suballeles with Behcet’s disease in patients of German and Turkish origin. Tissue Antigens 58:166-70
- Behcet H. 1937. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre im Mund, am Auge und an den Genitalien. Dermatol. Wschr. 105:1152-7
- Adamantiades B. 1930. A case of relapsing iritis with hypopion (in Greek). Archia Iatrikis Etairas (Proceedings of hte Medical Society of Athens):586-39
- Dilsen N. 1996. History and development of Behcet’s disease. Rev Rhum Engl Ed 63:512-9
- Zouboulis CC, Keitel W. 2002. A historical review of early descriptions of Adamantiades-Behet`s disease. J Invest Dermatol 1:201-5
- Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I. 2010. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet’s disease. Arthritis Rheum 62:2796-805
- Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. 2009. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906-13
- Deuter C, Kotter I, Mohle A, Vonthein R, Stubiger N, Zierhut M. 2009. Long-Term observations of vision and relapse-free intervals in patients with severe uveitis due to Behcet`smdisease treated with interferon alfa. ARVO Abstract 2009 No. 2694
- Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Foerster MH. 2008. Longterm visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896-903
- Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. 2006. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692-5
- Kotter I, Gunaydin I, Zierhut M, Stubiger N. 2004. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320-35
- Koetter I, Vonthein R, Zierhut M, Eckstein A, Ness T, et al. 2004. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trila. Semin Arthritis Rheum 33:311-9
- Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, et al. 2003. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet’s disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 528:521-3
- Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, et al. 2015. Apremilast for Behcet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med 372:1510-8
- Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, et al. 2018. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis 77:808-18
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, et al. 2013. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1-11
- International Team for the Revision of the International Criteria for Behcet’s D. 2014. The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338-47
- Dilsen N. 2003. The importance of the manifestations besides the ones included in international criteria for Behcet’s disease. Adv Exp Med Biol 528:105-8
- Barnes CG. 1999. Behcet’s syndrome–classification criteria. Ann Med Interne (Paris) 150:477-82
- Mason RM, Barnes CG. 1969. Behcet’s syndrome with arthritis. Ann Rheum Dis 28:95-103
- O’Duffy JD. 1981. Behcet’s disease. Minn Med 64:325-6
- Mizushima Y. 1988. [Revised diagnostic criteria for Behcet’s disease in 1987]. Ryumachi 28:66-70
- 1990. Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 335:1078-80